| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/TRI.12540 |
| P698 | PubMed publication ID | 25683513 |
| P50 | author | Mikael Hivelin | Q39065347 |
| P2093 | author name string | Thomas Leclerc | |
| Philippe Grimbert | |||
| Dominique Charron | |||
| Eric Bey | |||
| Christian Jacquelinet | |||
| Caroline Suberbielle | |||
| Laurent Lantieri | |||
| Patrick Duhamel | |||
| Laurent Bargues | |||
| Benoit Audry | |||
| P2860 | cites work | Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the Ross operation. | Q51524615 |
| Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques. | Q51558707 | ||
| Investigation of antibody-mediated rejection in composite tissue allotransplantation in a rat limb transplant model. | Q51746804 | ||
| Quality-of-life and outcome predictors following massive burn injury. | Q51926255 | ||
| Artificial Dermis for Major Burns | Q56621707 | ||
| The International Registry on Hand and Composite Tissue Transplantation | Q56681025 | ||
| Viability of cryopreserved human skin allografts: effects of transport media and cryoprotectant | Q57097633 | ||
| Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study | Q57698037 | ||
| An assessment of burn care professionals' attitudes to major burn. | Q30365257 | ||
| Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation | Q34124202 | ||
| Epidemiology of burns presenting to an accident and emergency department | Q34139481 | ||
| Alloantibody and xenoantibody cross-reactivity in transplantation | Q35629447 | ||
| Establishing transfusion needs in burn patients | Q36081109 | ||
| Sensitized recipients exhibit accelerated but not hyperacute rejection of vascularized composite tissue allografts | Q36778867 | ||
| Alemtuzumab as compared to alternative contemporary induction regimens. | Q36880514 | ||
| The Banff 2007 working classification of skin-containing composite tissue allograft pathology. | Q37150363 | ||
| Near-total human face transplantation for a severely disfigured patient in the USA. | Q37553444 | ||
| Calculated PRA (CPRA): the new measure of sensitization for transplant candidates | Q37643767 | ||
| End of life decisions and care of the adult burn patient. | Q37809193 | ||
| Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale | Q37990988 | ||
| Impact of donor-specific antibodies in reconstructive transplantation | Q38144106 | ||
| Facial transplantation: the first 9 years | Q38208373 | ||
| Antibody-mediated rejection despite inhibition of terminal complement. | Q38427447 | ||
| Viability of frozen allografts | Q41128241 | ||
| Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. | Q41849097 | ||
| Three patients with full facial transplantation | Q43789176 | ||
| Utilisation of glycerolised skin allografts in severe burns | Q44140738 | ||
| The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes | Q44174433 | ||
| Antibody-mediated rejection in hand transplantation | Q44484676 | ||
| C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SAB-IgG. | Q44559546 | ||
| Lessons learned from simultaneous face and bilateral hand allotransplantation. | Q44748607 | ||
| Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies | Q45332005 | ||
| Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation | Q45627897 | ||
| Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. | Q46060462 | ||
| Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches | Q46083436 | ||
| Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 | ||
| Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 | ||
| Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? | Q47880758 | ||
| Feasibility, reproducibility, risks and benefits of face transplantation: a prospective study of outcomes | Q48703208 | ||
| Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. | Q50618048 | ||
| The management of antibody-mediated rejection in the first presensitized recipient of a full-face allotransplant. | Q51141826 | ||
| Effects of different sensitization events on HLA alloimmunization in solid organ transplantation patients. | Q51362415 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 582-593 | |
| P577 | publication date | 2015-02-26 | |
| P1433 | published in | Transplant International | Q15762140 |
| P1476 | title | Anti-HLA sensitization in extensively burned patients: extent, associated factors, and reduction in potential access to vascularized composite allotransplantation. | |
| P478 | volume | 28 |
| Q54951741 | Absence of Rejection in a Facial Allograft Recipient with a Positive Flow Crossmatch 24 Months after Induction with Rabbit Anti-Thymocyte Globulin and Anti-CD20 Monoclonal Antibody. |
| Q39418200 | Accommodation and related conditions in vascularized composite allografts |
| Q57090884 | Advances in machine perfusion, organ preservation, and cryobiology: potential impact on vascularized composite allotransplantation |
| Q50220282 | Evaluation of human leukocyte antigen sensitization in burn patients after treatment with skin allografts and transfusion of blood products. |
| Q38827200 | Face transplant: long-term follow-up and results of a prospective open study |
| Q48051974 | Facial transplantation: facing the limits, planning the future. |
| Q36154218 | Hypertrophic scarring: the greatest unmet challenge after burn injury |
| Q38801341 | Immunological Effect of Skin Allograft in Burn Treatment: Impact on Future Vascularized Composite Allotransplantation |
| Q33877788 | Longitudinal immunological characterization of the first presensitized recipient of a face transplant |
| Q38649653 | Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions |
| Q38886875 | Vascularized Composite Allotransplantation-An Emerging Concept for Burn Reconstruction. |
| Q36669753 | Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration |
Search more.